Mice with defects in organised gut associated lymphoid tissue development induced by gene defects or by gestational or postgestational treatment (modified from Mebius7)
| Gene deficient/treated mice | PP | MLN | Reference |
|---|---|---|---|
| aly, alymphoplasia inducing gene; CC, CXC/R/L, CC, CX chemokine/receptor/ligand; G alpha i2, G protein αi2; Id2, inhibitor of the helix loop helix; γc, common cytokine receptor γ chain; Ikaros, member of the Kruppel family of zinc finger DNA binding proteins; ikkα, inhibitor of κBα; IL-7, interleukin 7; Jak3, janus kinase 3; LTα/β, -R, lymphotoxin α/β, -receptor; LTβRIgG, lymphotoxin β receptor-IgG fusion protein; MLN, mesenteric LN; NFκB, nuclear factor κB; NIK, NFκB inducing kinase; Relb, NFκB family transcription factor; Rorγ, retinoid related orphan receptor γ; PP, Peyer’s patches; TNF, tumour necrosis factor; TNFR, tumour necrosis factor receptor; TRAF, TNF receptor associated factor; TRANCE(R), TNF related activation induced cytokine (receptor). | |||
| LTα−/−, LTβR−/−, Nik−/−, aly/aly | − | – | 19, 20, 25, 81– 83 |
| NFκB2−/− | − | + | 84 |
| Relb−/− | − | – | 85 |
| LTβ−/− | − | + | 21, 26, 86 |
| Light−/− x LTβ−/− | − | <MLN than LTβ−/− | 34 |
| TNF−/− | Reduced number | + | 31, 87 |
| TNFR-I (55 kDa)−/− | Reduced number | + | 30, 31 |
| LTα−/+ x LTβ+/− | − | + | 88 |
| Galpha i2−/− | Reduced in number | + | 89, 90 |
| Ikkα−/− | − | Not done | 91 |
| Trance−/−, Trancer−/−, Traf 6−/− | + | − | 92– 95 |
| Ikaros−/− | − | − | 96, 97 |
| Rorγ−/− | − | − | 98, 99 |
| IL7R−/−, Jak3−/−, γc−/− | − | + | 12, 13, 16 |
| Id2−/− | − | − | 100 |
| IL-7−/− | − | ? | 15 |
| Cxcr5−/−, Cxcl 13−/− | 0–2 | Reduced number | 101, 102 |
| Gestational LTβRIgG treatment | − | + | 22 |
| Gestational LTβRIgG and TNFRIgG treatment | − | − or few | 24 |